NEW YORK — Eurofins Viracor said on Thursday that it has acquired an exclusive license to a sequencing-based liquid biopsy technology developed at Cornell University for tracking tissue damage in COVID-19 and transplant patients.
Eurofins Viracor said the technology has been used by its developers to create an assay that can scan for complications of hematopoietic cell transplantation. It can also be used to gauge the damage COVID-19 has on cells, tissues, and organs, as well as to identify the presence of urinary tract infections in kidney transplant patients and assess damage to the kidney and bladder.
The Lee's Summit, Missouri-based company said it intends to use the technology to develop and commercialize assays for all three applications.
Financial and other terms of the license with Cornell were not disclosed.
About a year ago, Eurofins Viracor acquired a license from the Cleveland Clinic for a urine biomarker test for detecting rejection in kidney transplant patients.